Not to be used for the treatment of type 1 diabetes. Patients for whom a dapagliflozin-induced drop in BP could pose a risk eg, those on antihypertensive therapy w/ history of hypotension or elderly patients. Careful monitoring of vol status (eg, physical exam, BP measurements, lab test including haematocrit & electrolytes) is recommended in case of intercurrent conditions that may lead to vol depletion (eg, GI illness). Discontinue immediately if diabetic ketoacidosis; Fournier's gangrene is suspected. Interrupt treatment in patients who are hospitalized for major surgical procedures or acute serious medical illnesses; monitoring of ketones is recommended. Increased risk of UTI; consider temporary interruption when treating pyelonephritis or urosepsis. Experience is limited in NYHA class IV. Counsel patients w/ diabetes on routine preventive foot care. +ve glucose in urine. Galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Not recommended in patients w/ eGFR <15 mL/min/1.73 m
2. Exposure is increased in patients w/ severe hepatic impairment. Discontinue if pregnancy is detected. Should not be used during breast-feeding. Safety & efficacy in childn <18 yr have not been established. Risk for vol depletion in elderly ≥65 yr.
Sign Out
